SEC Form 4 · accession 0001209191-19-006634
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander Cumbo
Officer — SVP, Chief Commercial Officer
Period of report
Feb 1, 2019
Accepted (ET)
Feb 1, 2019 · 8:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2019 | M | 2,250 | $13.90 | A | 25,016 | D | |
| Common Stock | Feb 1, 2019 | M | 5,250 | $26.24 | A | 30,266 | D | |
| Common Stock | Feb 1, 2019 | S | 15,000 | $140.00 | D | 15,266 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $13.90 | Feb 1, 2019 | M | 2,250 | D | Feb 27, 2016 | Feb 27, 2025 | Common Stock | 2,250 | 0 | D |
| Stock Option (right to buy) | $26.24 | Feb 1, 2019 | M | 5,250 | D | Jan 2, 2014 | Jan 2, 2023 | Common Stock | 5,250 | 46,965 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.